STOCK TITAN

Arbutus Biopharm - ABUS STOCK NEWS

Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.

Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical leader advancing novel therapies for chronic hepatitis B through RNA interference and lipid nanoparticle delivery systems. This page provides investors and industry observers with timely updates on the company’s scientific progress, regulatory milestones, and strategic partnerships.

Access consolidated news coverage of ABUS’s clinical trials, patent developments, and collaborative research initiatives. Our repository includes press releases on drug candidate advancements, financial disclosures, and peer-reviewed study outcomes – all essential for tracking this innovator’s pursuit of HBV functional cures.

Key updates cover three critical areas: clinical-stage developments targeting viral suppression, technology licensing agreements leveraging proprietary LNP platforms, and research publications validating therapeutic approaches. Regular monitoring ensures you stay informed about ABUS’s role in reshaping infectious disease treatment paradigms.

Bookmark this page for direct access to verified updates from Arbutus Biopharma and third-party analyses. Check back frequently to track how ABUS’s dual focus on antiviral therapies and delivery technologies positions it within the competitive biopharmaceutical landscape.

Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced its 2024 business outlook, including clinical development milestones for its HBV pipeline and a financial update. The company's strong balance sheet and anticipated clinical trial readouts position it well towards achieving its mission of developing a functional cure for patients with chronic hepatitis B virus (cHBV). The Phase 2a program for imdusiran, the company's RNAi therapeutic, reinforces the potential role of imdusiran as a cornerstone in a treatment regimen to functionally cure patients with cHBV. Additionally, AB-101, the company's oral PD-L1 inhibitor, continues to progress, with preliminary data expected from the ongoing Phase 1a/1b clinical trial. Arbutus also provided an update on the claim construction hearing for Moderna LNP litigation and its strong financial position with a cash runway into Q1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
none
-
Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) and Barinthus Biotherapeutics plc (BRNS) announced a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, presenting preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran, with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy. The data showed a meaningful reduction of HBsAg levels, robust reductions of HBsAg during the imdusiran treatment period, and preliminary immunology data suggesting HBV-specific T cell IFN-γ production is enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
-
Rhea-AI Summary
Arbutus Biopharma Corporation (ABUS) announced their participation in the Jefferies London Healthcare Conference on November 15, 2023, presenting their efforts in developing a cure for chronic hepatitis B virus (cHBV) infection. The live webcast of the presentation can be accessed at https://investor.arbutusbio.com/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences
Rhea-AI Summary
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported third-quarter 2023 financial results and provided a corporate update. They will be presenting preliminary data at AASLD from the first group of patients in its Phase 2a clinical trial evaluating imdusiran, nucleos(t)ide analogue (NA) therapy, and VTP-300, an HBV antigen-specific immunotherapy. Dosing continues in two Phase 2a combination clinical trials with imdusiran and in a Phase 1a/1b clinical trial with AB-101, their oral PD-L1 checkpoint inhibitor. They are reducing their workforce by 24% as a result of recent pipeline optimization. The cash runway has been extended into the first quarter of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
-
Rhea-AI Summary
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that William Collier will retire from his position as President and CEO, with Michael J. McElhaugh, Co-founder and COO, stepping in as Interim CEO effective January 1, 2024. The company expressed gratitude for Collier's leadership and confidence in McElhaugh's ability to advance Arbutus' pipeline and shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
none
-
Rhea-AI Summary
Arbutus Biopharma Corporation has announced that it will release its third quarter 2023 financial results and corporate update on November 7, 2023. The press release is scheduled for 7:30 a.m. ET and the conference call/webcast will take place at 8:45 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
conferences earnings
Rhea-AI Summary
Arbutus Biopharma to participate in H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
conferences
-
Rhea-AI Summary
Arbutus Biopharma to present clinical and preclinical data at The Liver Meeting® 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.61%
Tags
none
-
Rhea-AI Summary
Arbutus Biopharma announces pipeline updates, focusing on HBV assets imdusiran and AB-101, discontinuing coronavirus and oral RNA destabilizer programs. Cash runway extended through Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.73%
Tags
Rhea-AI Summary
Arbutus Biopharma to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Arbutus Biopharm

Nasdaq:ABUS

ABUS Rankings

ABUS Stock Data

605.08M
149.50M
22.26%
55.34%
4.44%
Biotechnology
Pharmaceutical Preparations
Link
United States
WARMINSTER